We are live on ! Find out more
II

Ishara Investments Portfolio holdings

AUM $136M
This Fund
S&P 500
This Quarter Est. Return
+20.83%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
+$30.5M
Cap. Flow
+$13.3M
Cap. Flow %
9.77%
Top 10 Hldgs %
50.98%
Holding
53
New
16
Increased
13
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$6.31M
2
INSM icon
Insmed
INSM
+$6.21M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$5.33M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.97M
5
TNXP icon
Tonix Pharmaceuticals
TNXP
+$4.36M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$5.57M
2
FOLD
Amicus Therapeutics
FOLD
+$5.34M
3
AXSM icon
Axsome Therapeutics
AXSM
+$5.33M
4
VSTM icon
Verastem
VSTM
+$4.35M
5
ARWR icon
Arrowhead Research
ARWR
+$3.47M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
1
Acadia Pharmaceuticals
ACAD
$5.27B
$10.4M 7.62%
410,000
+287,000
+233% +$6.31M
XERS icon
2
Xeris Biopharma Holdings
XERS
$1.59B
$9.74M 7.16%
1,230,000
+205,000
+20% +$1.31M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$12.8B
$8.21M 6.03%
143,500
+61,500
+75% +$3.37M
PRAX icon
4
Praxis Precision Medicines
PRAX
$10.3B
$7.55M 5.55%
22,550
– –
RARE icon
5
Ultragenyx Pharmaceutical
RARE
$2.61B
$6.84M 5.03%
205,000
+30,750
+18% +$764K
AGIO icon
6
Agios Pharmaceuticals
AGIO
$2.02B
$6.09M 4.47%
+164,000
New +$4.97M
INSM icon
7
Insmed
INSM
$27.1B
$5.46M 4.01%
+51,250
New +$6.21M
CRNX icon
8
Crinetics Pharmaceuticals
CRNX
$9B
$5.37M 3.95%
+143,500
New +$5.33M
ZNTL icon
9
Zentalis Pharmaceuticals
ZNTL
$367M
$4.97M 3.65%
1,025,000
-205,000
-17% -$818K
PCVX icon
10
Vaxcyte
PCVX
$9.09B
$4.77M 3.5%
82,000
+24,600
+43% +$1.34M
ANNX icon
11
Annexon
ANNX
$976M
$4.68M 3.44%
820,000
+645,750
+371% +$3.57M
TVTX icon
12
Travere Therapeutics
TVTX
$6.32B
$4.66M 3.42%
82,000
-28,700
-26% -$1.27M
TNXP icon
13
Tonix Pharmaceuticals
TNXP
$234M
$4.32M 3.17%
+338,250
New +$4.36M
BBIO icon
14
BridgeBio Pharma
BBIO
$15.7B
$4.28M 3.14%
+57,400
New +$4.02M
AXSM icon
15
Axsome Therapeutics
AXSM
$10.8B
$4.01M 2.95%
16,400
-24,600
-60% -$5.33M
CTNM
16
Contineum Therapeutics
CTNM
$641M
$3.36M 2.47%
205,000
+63,000
+44% +$826K
LXRX icon
17
Lexicon Pharmaceuticals
LXRX
$1.04B
$3.05M 2.24%
1,271,000
+369,000
+41% +$719K
KURA icon
18
Kura Oncology
KURA
$1.21B
$3.04M 2.23%
+276,750
New +$2.61M
DBVT
19
DBV Technologies
DBVT
$941M
$3.03M 2.22%
184,500
+82,000
+80% +$1.55M
GMAB icon
20
Genmab
GMAB
$21.1B
$2.82M 2.07%
102,500
+20,500
+25% +$545K
CYTK icon
21
Cytokinetics
CYTK
$10.8B
$2.79M 2.05%
+32,800
New +$2.36M
MLYS icon
22
Mineralys Therapeutics
MLYS
$2.33B
$2.77M 2.03%
102,500
+20,500
+25% +$562K
SLN
23
Silence Therapeutics
SLN
$850M
$2.43M 1.79%
55,350
-85,150
-61% -$599K
NUVB icon
24
Nuvation Bio
NUVB
$2.49B
$2.1M 1.54%
+369,000
New +$1.8M
WVE icon
25
Wave Life Sciences
WVE
$1.03B
$1.91M 1.4%
+328,000
New +$2.17M
1
2 3

Similar funds

SB
Semitam Bonam Goshen, New York $136M AUM 13.42% 1-Year Est. Return
WFA
WJ Financial Advisors Killingworth, Connecticut $136M AUM 23.45% 1-Year Est. Return
RC
Rahlfs Capital Lake Kiowa, Texas $136M AUM 33.89% 1-Year Est. Return
GBFP
Golden Bell Financial Planning Alpharetta, Georgia $136M AUM 12.99% 1-Year Est. Return
RIA
Rhodes Investment Advisors Fort Worth, Texas $136M AUM
RCWM
Red Crane Wealth Management San Francisco, California $136M AUM 18.56% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
HMS
Hanseatic Management Services Albuquerque, New Mexico $136M AUM

Ishara Investments's Q2 2026 Portfolio in Review

As of Q2 2026, Ishara Investments held 53 positions worth $136M, up 29% from $106M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Ishara Investments deployed $13.3M of net new capital in Q2 2026, opening 16 new positions and adding to 13 existing holdings. Its largest new stake was Insmed: 51,250 shares worth $5.46M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $5.33M trimmed.

  • Ishara Investments's largest Q2 2026 buy was Insmed: 51,250 shares worth $5.46M.
  • Ishara Investments added most to Acadia Pharmaceuticals in Q2 2026, an estimated $6.31M increase.
  • Ishara Investments's biggest Q2 2026 reduction was Axsome Therapeutics, cutting an estimated $5.33M.
  • Ishara Investments fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $5.57M.
  • Ishara Investments's ten largest holdings make up 51% of its $136M portfolio in Q2 2026.
  • Ishara Investments opened 16 new positions and closed 12 in Q2 2026.
  • Ishara Investments's portfolio value rose 29% quarter-over-quarter to $136M.

Based on Ishara Investments's 13F filing for Q2 2026, filed 14 Aug 2026.